CM
TEVA icon

Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-251,784
Closed -$8.36M – 95
2017
Q2 		$8.36M Buy
251,784
+14,074
+6% +$436K 2.5% 14
2017
Q1 		$7.63M Buy
237,710
+85,367
+56% +$2.91M 2.36% 17
2016
Q4 		$5.52M Buy
152,343
+5,391
+4% +$215K 1.84% 27
2016
Q3 		$6.76M Buy
146,952
+629
+0.4% +$32.8K 2.5% 15
2016
Q2 		$7.35M Buy
146,323
+4,629
+3% +$246K 2.85% 12
2016
Q1 		$7.58M Sell
141,694
-5,502
-4% -$323K 2.93% 12
2015
Q4 		$9.66M Buy
147,196
+489
+0.3% +$30.2K 3.67% 3
2015
Q3 		$8.28M Sell
146,707
-25,343
-15% -$1.64M 3.33% 6
2015
Q2 		$10.2M Sell
172,050
-1,251
-0.7% -$77.2K 3.53% 3
2015
Q1 		$10.8M Sell
173,301
-805
-0.5% -$46.8K 3.65% 4
2014
Q4 		$10M Buy
174,106
+935
+0.5% +$52.1K 3.09% 8
2014
Q3 		$9.31M Sell
173,171
-480
-0.3% -$25.4K 3.08% 9
2014
Q2 		$9.1M Sell
173,651
-3,150
-2% -$161K 2.94% 11
2014
Q1 		$9.34M Sell
176,801
-51,123
-22% -$2.36M 3.18% 8
2013
Q4 		$9.13M Buy
227,924
+9,173
+4% +$361K 3.17% 10
2013
Q3 		$8.26M Buy
218,751
+11,515
+6% +$449K 3.19% 8
2013
Q2 		$8.12M Buy
+207,236
New +$8.07M 3.38% 8

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital Management's TEVA Position: Q3 2017 in Review

Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 251,784 shares — an estimated $8.36M sold.

Capital Management first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $10.8M in Q1 2015. 536 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Capital Management sold 251,784 Teva Pharmaceuticals shares in Q3 2017, an estimated $8.36M.
  • Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 17 quarters.
  • Capital Management's Teva Pharmaceuticals position peaked at $10.8M in Q1 2015.
  • 536 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Capital Management's 13F filing for Q3 2017, filed 1 Nov 2017.